

Supplementary Table 1. Functional outcomes and serum PSA changes

Variable	Baseline	Postop 3 months	Postop 6 months	P-value ^{a)}
Uroflowmetry and PVR				
Maximum flow rate (mL/sec)	9.3±4.7	21.5±10.9	22.0±13.2	0.002
PVR (mL)	130.5±169.0	88.5±93.5	64.2±75.1	<0.001
IPSS				
IPSS-storage symptom score	8.0±4.6	5.6±4.9	4.4±4.9	<0.001
IPSS-obstructive symptom score	11.8±6.7	3.7±6.8	3.6±6.8	<0.001
IPSS-total score	19.8±10.5	8.6±11.0	7.5±11.1	<0.001
IPSS, quality of life score	4.2±1.5	1.9±1.9	1.6±1.9	<0.001
PSA total (ng/mL)	4.0±4.1	-	1.0±0.9	<0.001
Low-PSA group	1.6±0.8	-	0.8±0.5	<0.001
High-PSA group	6.9±4.7	-	1.2±1.1	<0.001

Values are presented as mean ± standard deviation.

PSA, prostate-specific antigen; Postop, postoperative; PVR, postvoided residual volume; IPSS, International Prostate Symptom Score.

^{a)}Paired t-test was used to compare baseline and follow-up at 6 months; low-PSA group, baseline PSA < 3.0ng/mL; high-PSA group, baseline PSA ≥ 3.0 ng/mL.

Supplementary Table 2. Characteristics associated with PSA using univariable and multivariable regression analysis

Variable	Univariable analysis		Multivariable analysis	
	Unadjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value
AUR	2.389 (1.828–3.122)	<0.001	1.928 (1.435–2.596)	<0.001
IPSS	0.727 (0.392–1.346)	0.309	0.779 (0.394–1.549)	0.47
TPV	8.368 (5.560–12.596)	<0.001	7.166 (4.734–11.208)	<0.001
BOOI	2.396 (1.912–3.000)	<0.001	2.030 (1.591–2.593)	<0.001

PSA, prostate-specific antigen; CI, confidence interval; AUR, acute urinary retention; IPSS, International Prostate Symptom Score; TPV, total prostate volume; TZV, transitional zone volume; BOOI, Bladder Outlet Obstruction Index.